There are currently 90 active clinical trials seeking participants for Gastric Cancer research studies. The states with the highest number of trials for Gastric Cancer participants are California, New York, Ohio and Texas.
The GAstric Precancerous Conditions Study
NCT04191551
Recruiting
Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer. The Gastric Precancerous Conditions Study (GAPS) is an ob... Read More
Gender:
ALL
Ages:
Between 35 years and 84 years
Trial Updated:
11/27/2024
Locations: Stanford University, Stanford, California
Conditions: Gastric Cancer, Intestinal Metaplasia of Gastric Mucosa, Helicobacter Pylori Infection, Atrophic Gastritis
Register for Updates
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
NCT05379972
Recruiting
This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/22/2024
Locations: University of Colorado Health, Aurora, Colorado +3 locations
Conditions: Gastric Cancer, GastroEsophageal Cancer
Register for Updates
Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03259867
Recruiting
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/19/2024
Locations: University of California, Irvine, Orange, California +2 locations
Conditions: Hepatocellular Carcinoma, Gastric Cancer
Register for Updates
Avutometinib and Defactinib in Diffuse Gastric Cancer
NCT06487221
Recruiting
The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Gastric Cancer, Stomach Cancer
Register for Updates
Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379
Recruiting
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Precision NextGen Oncology, Beverly Hills, California +1 locations
Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Register for Updates
The Gastric Cancer Foundation: A Gastric Cancer Registry
NCT01514045
Recruiting
The Gastric Cancer Registry will combine data acquired directly from patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene via an online questionnaire with genomic data obtained from saliva, blood and tissue samples. The purpose of this registry is to gain better understanding of the causes of gastric cancer, both environmental and genetic; whether certain genomic data... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Stanford University, School of Medicine, Stanford, California
Conditions: Gastric Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT02838836
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri
Conditions: Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
NCT03551951
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: Harry S Truman Veterans Memorial Hospital, Columbia, Missouri
Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
NCT04725994
Recruiting
This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: USC Norris Comp. Cancer Ctr Hospital, Los Angeles, California +13 locations
Conditions: Gastric Cancer
Register for Updates
A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: The Oncology Institute of Hope & Innovation, Anaheim, California +82 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Register for Updates
CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT04368702
Recruiting
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Brigham & Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Register for Updates
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692
Recruiting
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +14 locations
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Cutaneous Melanoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, Colorectal Cancer (MSI-H), MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer
Register for Updates